The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the ...

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents ...

(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II ...

Paul Chaplin, President & CEO of Bavarian Nordic, said: "We applaud EMA for their expedited review and decision to recommend approval of MVA-BN for adolescents. This represents an important milestone ...

Mpox, declared a global public health emergency by WHO, has disproportionately affected children and adolescents ...

Bavarian Nordic's mpox vaccine has gained approval for use in adolescents by the EU's drug regulator. This move is seen as ...

LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in ...

EU drug regulator approves use of Bavarian Nordic's mpox vaccine, Imvanex for adolescents: Copengagen, Denmark Saturday, September 21, 2024, 10:00 Hrs [IST] Bavarian Nordic A/S, a ...

The U.K. government has secured over 150,000 doses of the mpox vaccine from Bavarian Nordic A/S (OTC:BVNRY) (OTC:BVNKF) to ...

The European Commission has greenlit Bavarian Nordic’s mpox and smallpox vaccine for approval for kids aged 12 to 17. The European Medicines Agency carried out an expedited and positive review of the ...

Bavarian Nordic has also submitted clinical data to the European Medicines Agency (EMA) to support the extension of the Imvanex (MVA-BN) smallpox and mpox vaccine indication to include adolescents ...

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.